Invitation to Vimian’s Interim Report for the second quarter of 2023

News
Aug 07 2023

Invitation to Vimian’s Interim Report for the second quarter of 2023

Vimian Group AB will publish its Interim Report for the second quarter of 2023 on Thursday, 17 August 2023, at 07.45 (CET). An audiocast will be organised for investors, analysts and media, on the same day at 09.00 (CET).

CEO, Fredrik Ullman and CFO, Carl-Johan Zetterberg Boudrie, will present and comment on the report. Magnus Kjellberg, CEO of Vimian’s Specialty Pharma segment Nextmune, will provide a brief update on Nextmune. The audiocast will be held in English and include a question-and-answer session

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
Link: https://conference.financialhearings.com/teleconference/?id=5004723

To attend the webcast:
Link: https://ir.financialhearings.com/vimian-group-q3-report-2023

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.

About Vimian

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 15,000 veterinary clinics and 1,700 labs, sells to over 90 markets, has 1,000 employees and annual revenues of approximately EUR 280 million. For more information, please visit: www.vimian.com. FNCA Sweden AB is appointed the Company’s Certified Adviser.